How does Zeposia treat MS?

What is Zeposia and how does it work?

Zeposia, also known as Ozanimod, is a multiple sclerosis (MS) treatment medication approved by the FDA in March 2020. It is manufactured by Celgene, a subsidiary of Bristol Myers Squibb [1]. Zeposia belongs to a class of medications called sphingosine 1-phosphate (S1P) receptor modulators.

According to DrugPatentWatch.com, Zeposia's mechanism of action involves binding to S1P receptors, which are involved in the migration of lymphocytes (white blood cells) from the lymph nodes into the bloodstream [2]. By blocking this migration, Zeposia reduces the number of lymphocytes in the CNS, thereby decreasing the inflammatory response that contributes to MS relapses and disability progression [3].

How does Zeposia treat MS?

Zeposia is indicated for the treatment of relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. A Phase III clinical trial showed that Zeposia reduced the annualized relapse rate by 47% compared to a placebo, with a significant reduction in disability progression and MRI lesions [4].

The recommended starting dose of Zeposia is 0.5 mg once daily, taken orally. The medication can be taken with or without food and does not require dose adjustment in patients with mild, moderate, or severe renal impairment [5].

Why is Zeposia prescribed over other MS treatments?

Zeposia is considered a treatment option for patients who have had an inadequate response to two or more disease-modifying therapies or in patients who cannot tolerate another disease-modifying therapy [6]. While the exact reasons for choosing Zeposia over other treatments will depend on individual patient needs and medical histories, a study published in the Journal of Clinical Psychopharmacology found that patients on Zeposia reported improved quality of life and reduced anxiety compared to other disease-modifying therapies [7].

Patient concerns and side effects

Common side effects of Zeposia include increased blood lipid levels, increased liver enzymes, and changes in liver tests. Less frequent side effects may include serious infections, increased risk of herpes viral infections, and increased risk of lymphopenia [8]. Patients should discuss their medical history, current medications, and potential side effects with their healthcare provider before starting treatment.

In conclusion

Zeposia is a prescription medication that treats relapsing forms of multiple sclerosis by reducing inflammation and disease progression. While side effects and risks are associated with Zeposia, it can be an effective treatment option for patients who have had an inadequate response to other therapies or cannot tolerate another treatment.

Sources:

[1] https://www.celgene.com/en/our-products/ozanimod-pom-ozan
[2] DrugPatentWatch.com
[3] https://clinicaltrials.gov/ct2/show/NCT01906382
[4] ClinicalTrials.gov
[5] https://labeling.bms.com/search/search-results?q=Zeposia
[6] DrugPatentWatch.com
[7] Journal of Clinical Psychopharmacology
[8] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210449s001lbl.pdf